Riskpilot← Back to searchSign inGet full accessInverna Therapeutics ApS
APSActiveCVR 45161641Cortex Park 26E, 1.Research and experimental development on natural sciences and engineering · NACE 7210Est. 2024— employees
Revenue 2024
—
EBITDA margin
—
Equity ratio
94.8%
Financial strength
Net profit 2024
DKK -159K
| Revenue | — | — |
| EBITDA | DKK -159K | — |
| Net profit | DKK -159K | — |
| Total assets | DKK 3,8M | — |
| Equity | DKK 3,6M | — |
| Employees | — | — |
Legal name
Inverna Therapeutics ApS
CVR number
45161641
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22. oktober 2024
Share capital
DKK 105.144
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af formanden for bestyrelsen i forening med et medlem af bestyrelsen, to medlemmer af
bestyrelsen eller af den samlede bestyrelse
Company purpose
Selskabets formål er research, udvikling og kommercialisering af farmaceutiske produkter og aktiviteter forbundet hermed
Address
Cortex Park 26E, 1.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | — |
| Staff expenses | -0 |
| EBITDA | -159 |
| Depreciation & amort. | -0 |
| EBIT | -159 |
| Net financials | 0 |
| Profit before tax | -159 |
| Tax | -0 |
| Net profit | -159 |
| Item | 2024 |
|---|---|
| Total assets | 3.802 |
| Equity | 3.606 |
| Long-term debt | 0 |
| Short-term debt | 196 |
| Total debt | 196 |
EBITDA margin
-15889700.0%
This company
15.8%
Market median
-100567822% vs market
20242024
Equity ratio
94.8%
This company
38.2%
Market median
+148% vs market
20242024
Return on equity
-4.4%
This company
18.4%
Market median
-124% vs market
20242024
Net profit margin
-15889700.0%
This company
8.1%
Market median
-196169236% vs market
20242024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20242024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20242024
- Annual report 2024Filed via CVR / Virk · Period 2024-10-22 – 2024-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
US | Founder | 2024 | — | — |
LL Founder | Founder | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 50.0% | 50.0% | 2025 | |
| Individual | 10.0% | 10.0% | 2025 | |
SCIENCE VENTURES DENMARK A/S | Company | 5.0% | 5.0% | 2024 |
| Individual | 5.0% | 5.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Syddansk Universitet (University of Southern Denmark)SCIENCE VENTURES DENMARK A/S
Inverna Therapeutics ApS (this company)Board members of Inverna Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulrika Simone Spangsberg Petersen | Founder | 0 companies |
| Lise Lolle Holm | Founder | 0 companies |
| Mads Aaboe Jensen | Board of Directors | 0 companies |
| Pontus Fredrik Gunnar Klein | Board of Directors | 0 companies |
| Poul Sørensen | Chairman | 0 companies |